Back to Search Start Over

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

Authors :
Roe MT
Armstrong PW
Fox KA
White HD
Prabhakaran D
Goodman SG
Cornel JH
Bhatt DL
Clemmensen P
Martinez F
Ardissino D
Nicolau JC
Boden WE
Gurbel PA
Ruzyllo W
Dalby AJ
McGuire DK
Leiva-Pons JL
Parkhomenko A
Gottlieb S
Topacio GO
Hamm C
Pavlides G
Goudev AR
Oto A
Tseng CD
Merkely B
Gasparovic V
Corbalan R
Cinteză M
McLendon RC
Winters KJ
Brown EB
Lokhnygina Y
Aylward PE
Huber K
Hochman JS
Ohman EM
Source :
The New England journal of medicine [N Engl J Med] 2012 Oct 04; Vol. 367 (14), pp. 1297-309. Date of Electronic Publication: 2012 Aug 25.
Publication Year :
2012

Abstract

Background: The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated.<br />Methods: In this double-blind, randomized trial, in a primary analysis involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 months of treatment with prasugrel (10 mg daily) versus clopidogrel (75 mg daily). In a secondary analysis involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel versus 75 mg of clopidogrel.<br />Results: At a median follow-up of 17 months, the primary end point of death from cardiovascular causes, myocardial infarction, or stroke among patients under the age of 75 years occurred in 13.9% of the prasugrel group and 16.0% of the clopidogrel group (hazard ratio in the prasugrel group, 0.91; 95% confidence interval [CI], 0.79 to 1.05; P=0.21). Similar results were observed in the overall population. The prespecified analysis of multiple recurrent ischemic events (all components of the primary end point) suggested a lower risk for prasugrel among patients under the age of 75 years (hazard ratio, 0.85; 95% CI, 0.72 to 1.00; P=0.04). Rates of severe and intracranial bleeding were similar in the two groups in all age groups. There was no significant between-group difference in the frequency of nonhemorrhagic serious adverse events, except for a higher frequency of heart failure in the clopidogrel group.<br />Conclusions: Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed. (Funded by Eli Lilly and Daiichi Sankyo; TRILOGY ACS ClinicalTrials.gov number, NCT00699998.).

Details

Language :
English
ISSN :
1533-4406
Volume :
367
Issue :
14
Database :
MEDLINE
Journal :
The New England journal of medicine
Publication Type :
Academic Journal
Accession number :
22920930
Full Text :
https://doi.org/10.1056/NEJMoa1205512